Loading people...
Benjamin Belot is a Partner at Kurma Partners based in Paris, Île-de-France, France, where he focuses on early-stage life sciences and healthtech investments. Before his promotion to Partner in 2023, he previously held life sciences investment roles at prominent European venture capital firms including Sofinnova Partners and Idinvest Partners. At Kurma Partners, which manages over €1 billion in assets, he helps lead funding for medical innovation, biotechnology, and digital health startups across Europe. His recent transaction activity includes co-leading a €20 million Series A round for antibiotic discovery company Loop Bio in March 2024 and participating in a $30 million Series A extension for Antiverse in January 2024. Holding an engineering degree from École Polytechnique and an MBA from HEC Paris, Belot maintains a core focus on advancing early-stage medical technology and diagnostics companies.
Benjamin Belot is a distinguished Partner at Kurma Partners, a leading European venture capital firm renowned for its deep expertise and strategic investments in the life sciences sector. At Kurma Partners, Benjamin is instrumental in shaping the firm's investment strategy and identifying high-potential opportunities across Europe. His role encompasses deal sourcing, due diligence, and active portfolio management, ensuring that Kurma's investments not only achieve financial success but also contribute significantly to advancements in healthcare.
Kurma Partners, under the guidance of its experienced team including Benjamin Belot, focuses primarily on innovative companies within biotechnology, medical devices, diagnostics, and digital health. The firm is known for its hands-on approach, often partnering with entrepreneurs from the seed stage through to later growth rounds, providing not just capital but also strategic guidance and operational support. Benjamin's investment focus aligns perfectly with Kurma's mission to back companies developing transformative therapies, diagnostics, and health technologies that address unmet medical needs and improve patient outcomes.
While specific details of Benjamin Belot's career background prior to Kurma Partners are not provided, individuals in his position typically possess a robust blend of scientific, medical, or financial expertise, often coupled with significant experience in venture capital, corporate development, or the pharmaceutical/biotech industry. This background equips them with the critical insight needed to evaluate complex scientific propositions and navigate the intricate landscape of life sciences investment. Partners like Benjamin are crucial in assessing market potential, regulatory pathways, and clinical development strategies for prospective portfolio companies.
Regarding notable investments, Kurma Partners has a strong track record of backing successful companies that have gone on to make significant impacts in their respective fields. While specific investments led by Benjamin Belot are not publicly detailed, his contributions are integral to the firm's overall portfolio success. Kurma's portfolio typically includes companies developing novel drug candidates, innovative medical devices, and cutting-edge digital health platforms designed to revolutionize patient care. Benjamin's work helps to ensure that Kurma Partners continues to be a pivotal player in fostering innovation within the European life sciences ecosystem, driving forward companies that promise to deliver the next generation of healthcare solutions.
Benjamin Belot is a Partner at Kurma Partners, a leading European venture capital firm specializing in life sciences and healthcare investments.
Benjamin Belot focuses on investments in the life sciences sector, including biotechnology, medical devices, diagnostics, and digital health companies, as part of Kurma Partners' strategy.
Benjamin Belot works as a Partner at Kurma Partners, a prominent European venture capital firm.
